Novartis Ag

Daniela Cipolletta

Jennifer Brogdon

Glenn Dranoff

Zhu Alexander Cao

John Scott Cameron

Deborah A Knee

Fei Wang

Kenzie MacIsaac

Marie-Louise Fjaellskog

Kenzie Macisaac

The present application n relates to a pharmaceutical composition comprising a PD-1 antibody and an M-CSF antibody. The combination can be administered independently or separately, in a quantity which is therapeutically effective for the treatment of cancer.

Combined use of anti PD-1 and anti M-CSF antibodies in the treatment of cancer

The present invention provides antibody compositions, including, e.g., antibodies, engineered antibodies and antibody fragments that bind to a tumor necrosis factor receptor superfamily member (i.e., 18). Provided compositions are useful in enhancing CD4+ and CD8+ T cell responses, and in the treatment, amelioration and prevention of diseases that can be counteracted with an augmented immune response, e.g., cancers. Also provided in the invention are polynucleotides and vectors that encode such molecules and host cells that harbor the polynucleotides or vectors; as well as pharmaceutical compositions that comprise such molecules and methods of use thereof.

Compositions and methods of use for augmented immune response and cancer therapy

Growing community of inventors

Arlington, MA, United States of America

Daniela Cipolletta